A boxed warning for lactic acidosis has been added to the label for Metformin Hydrochloride, effective 2026-07-29. This significant label revision, considered the strongest warning that the FDA requires, highlights the severe risks associated with metformin. It notes that postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The warning also points out that the onset of metformin-associated lactic acidosis is often subtle.
What this means
The addition of a boxed warning to the Metformin Hydrochloride label, effective 2026-07-29, signifies a critical update for clinicians and patients regarding the risk of lactic acidosis. This warning mandates that healthcare providers prioritize patient education on the signs and symptoms of this potentially life-threatening condition. The label explicitly details severe postmarketing outcomes, including death, hypothermia, hypotension, and resistant bradyarrhythmias, which underscore the urgency of early detection and management. Given that the onset of metformin-associated lactic acidosis is often subtle, clinicians must maintain a high index of suspicion, particularly in patients with predisposing factors such as renal impairment, concomitant use of certain drugs, or conditions leading to tissue hypoperfusion. Patients should be advised to seek immediate medical attention if they experience symptoms like malaise, myalgia, respiratory distress, increasing somnolence, or abdominal distress. The FDA's action to include this prominent warning ensures that the serious nature of metformin-associated lactic acidosis is clearly communicated, guiding safer prescribing practices and enhancing patient vigilance against this severe adverse event.
Source
This information is based on an FDA label revision for Metformin Hydrochloride, effective 2026-07-29. The full details of the label change are available on dailymed.nlm.nih.gov.